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Abstract objectives Hepatitis C virus (HCV) prevalence is poorly mapped in the East African region; with
the advent of novel HCV therapies, better epidemiological data are required to target the infection.
We sought to estimate HCV prevalence in healthy Malawian mothers and assess mother-to-child
transmission (MTCT); context is provided by reviewing previously published HCV prevalence data
from the region.
methods Using ELISA screening and confirmatory blot, serological testing of 418 healthy Malawian
mothers for HCV was performed. To examine MTCT, the children of any positive women were also
tested for HCV; all children had malignant disease unrelated to hepatocellular carcinoma. We
compared our results to published literature on HCV prevalence in Malawi and its neighbouring
countries.
results Three of 418 women were HCV reactive by ELISA; two were confirmed positive by
immunoblot (0.5%). One child of an HCV-infected mother was HCV seropositive. The literature
review revealed HCV prevalence ranging from 0 to 7.2% in the region, being highest in Tanzania
and specifically for cohorts of inpatients and HIV-co-infected people. The overall estimated
prevalence of HCV in Malawi was 1.0% (95%CI 0.7–1.4) when all studies were included (including
this one), but lower in healthy cohorts alone at 0.3% (95%CI 0.1–1.2).
conclusions This is the first study using confirmatory tests to examine HCV prevalence in healthy
Malawian mothers; the prevalence was low. Future studies need to address the source of infection in
healthy women.
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Introduction
Hepatitis C virus causes hepatitis, cirrhosis and hepato-
cellular carcinoma [1]. It is a bloodborne infection and
prevalent among intravenous drug users (IVDU) [2] and
men who have sex with men (MSM), particularly those
with HIV co-infection [3, 4] and their contacts. African
and Asian countries are thought to have the highest bur-
den of infection, but current prevalence estimates are var-
iable [5]. In Malawi, the reported prevalence of HCV in
healthy blood donors ranges from 0.1% to 18% [6, 7].
Heterosexual transmission has been reported as an unli-
kely route of transmission in Malawi [8]. Other modes of
transmission, such as iatrogenic spread in medical facili-
ties, or among intravenous drug users, are thought to be
rare [9, 10]. A study from Tanzania, a neighbouring
country, reports that MTCT is low [11], but this has not
been assessed in Malawi.
We examined the prevalence of HCV retrospectively
as part of an ongoing study of infections and cancers
among children in Malawi [12]. We report our findings
in the context of previous HCV prevalence studies from
Malawi and its neighbouring countries by way of a
comprehensive literature review. Mapping HCV preva-
lence is a prelude to possible eradication of HCV in
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lower income countries [13] following recent success
with novel HCV therapies [14].
Materials and methods
Sera from 418 paired Malawian women and their chil-
dren were collected between 2006 and 2010 and stored
at 80 °C until testing. Samples had been originally
collected as part of a childhood malignancy and blood-
borne virus (BBV) study at the Queen Elizabeth Central
Hospital in Blantyre, Malawi [12]. The majority of
children had been diagnosed with Burkitt’s lymphoma
and the remainder had a range of other tumours. Ethi-
cal approval for the study was obtained from the
Oxford Tropical Research Ethics Committee and the
Malawian College of Medicine Research and Ethics
Committee. Details of the original study are published
elsewhere [12].
Sera from the healthy women were screened in dupli-
cate by MP Diagnostics HCV ELISA 3.0 following
manufacturer’s instructions (MP Biomedicals, Cam-
bridge, UK). Borderline and reactive samples were
retested. Repeatedly ELISA reactive sera underwent
confirmatory testing using HCV BLOT 3.0 (MP Bio-
medicals). Positivity was defined according to the man-
ufacturer’s guidelines. Sera of children of HCV-positive
mothers were tested using both ELISA and immuno-
blot. The ELISA used in this study tests for the detec-
tion of antibodies in sera towards the HCV antigens
NS5, NS3 (c 200), NS4 (c 200) and the core (c22); the
strip immunoblots are a qualitative enzyme immunoas-
say and contain recombinant HCV proteins from the
capsid, NS3, NS4 and NS5 regions of the HCV gen-
ome; higher sensitivity is reported for the immunoblots
compared to the ELISA.
For the comprehensive review, PubMed was searched
in March 2014 using methods appropriate for system-
atic review; the search terms were as follows: ‘HCV’
or ‘Hepatitis C’ in combination with ‘Malawi’,
‘Mozambique’, ‘Tanzania’ or ‘Zambia’. Data of demo-
graphic factors, cohort size, HCV prevalence and
whether or not a confirmatory test (CT) was employed
were extracted. Publications were excluded that only
reported reactive screening tests in the absence of CT,
HCV prevalence in refugee cohorts and in patients with
jaundice or liver disease. Total HCV prevalence by
country, standard error and 95% confidence interval,
using the Wilson interval to take account of the small
anticipated prevalence, were calculated where more
than one study was available.
Informed and written consent was obtained from all
participants according to Oxford Tropical Research
Ethics Committee and the Malawian College of Medi-
cine Research and Ethics Committee ethics.
Results
HCV screening
Paired sera from 418 paired Malawian women and
children were available for testing. All children
attended the hospital for childhood malignancies; none
had hepatocellular carcinoma. At the time of sampling,
the children were of a mean age of 6.6 years. Three of
418 mothers’ sera were repeatedly HCV ELISA reac-
tive. Two reactive samples were confirmed to be posi-
tive by immunoblot. All three children of these mothers
were ELISA non-reactive, but the serum of one of these
children was repeatedly HCV positive in the more sen-
sitive immunoblot test. We therefore report two (0.5%)
HCV-positive mothers and one HCV-positive child. The
51-year-old HCV-positive woman with a HCV-negative
child was HIV negative and reported one lifetime
sexual partner. The second positive mother was also
HIV negative and reported one lifetime sexual partner;
her HCV-positive daughter was 4 years of age, HIV
negative and had no blood transfusion history. Fresh
whole blood was unavailable; therefore, HCV RNA
levels could not be measured to report disease activity.
Comprehensive review
To increase our understanding of the HCV prevalence
in the East African region around Malawi, we con-
ducted a comprehensive review of published HCV prev-
alence data. Our search returned a total of 50 studies,
of which 14 met the inclusion criteria. Of those, four
publications were from Malawi, three from Mozam-
bique, six from Tanzania and one from Zambia
(Table 1). The HCV prevalence ranged from 0% to
7.2% and was highest regionally in Tanzania and for
patient cohorts of hospital inpatients and HIV-co-
infected people. The prevalence rates aggregated by
country are summarised in Table 2. The overall esti-
mated prevalence of HCV in Malawi was 1.0% (95%
CI 0.7–1.4) when all studies were included, including
the one reported here, but was much lower in healthy
cohorts alone at 0.3% (95%CI 0.1–1.2). The HCV
prevalence in Tanzania appeared higher (2.1% [95%CI
1.6–2.6]), but this might be due to high prevalence of
HCV in just one study among apparently healthy
women [15]. In our analysis, Mozambique had an
HCV prevalence intermediate between Malawi and
Tanzania; Zambia’s prevalence was similar to healthy
© 2015 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd. 639
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Malawians, but only one study met our inclusion crite-
ria (Table 2).
Discussion
This seroprevalence study of HCV in paired mothers and
their children in Malawi detected a low HCV prevalence
of 0.5% in a cohort of healthy women who represent the
female general population of Malawi. Our review showed
that HCV prevalence is low in healthy adult volunteers
and blood donors in the East African region, but higher
among individuals who were hospitalised or HIV co-
infected [9, 16]. Tanzania has the highest and Zambia
the lowest reported HCV prevalence. Our literature
review purposefully concentrated upon Malawi and its
neighbouring countries and only included studies that
used comparable methodological stringency (screening +
confirmation); other reviews on HCV prevalence in
Africa, which include some data for these East African
nations, are available for HIV-co-infected individuals [5,
17], pregnant women [18] and general populations [19].
Although we confirmed low prevalence of HCV in
healthy women, one of two children of HCV-positive
mothers was HCV positive. A study from Tanzania
reported no MTCT in 43 children born to HCV-positive
mothers [11].
The exact transmission risk factors for our cohort
remain uncertain. In general, contaminated-needle re-
usage or contaminated-needle-stick injuries, contaminated
blood transfusions and unprotected sexual intercourse,
especially in HIV-positive men, are highly associated with
HCV transmission.
Blood transfusions are routinely tested for HCV in
Malawi, but we are not aware of needle exchange pro-
grammes for harm reduction. HCV prevalence in IVDU
and HIV-positive MSM has not been studied extensively
Table 1 Published prevalence of HCV in Malawi and its neighbouring countries
First author/publication year Nation Cohort (n) Healthy Non-healthy Sex HCV prevalence (%)
Chimphambano et al. [20] Malawi 142 HV M 0.0
22 HV F 0.0
Nyirenda et al. [9] Malawi 77 IP M 2.6
125 IP F 5.6
Moore et al. [16] Malawi 299 HIV+ ND 5.7
Chasela et al. [7] Malawi 2040 HIV+ PW F 0.1
Dazza et al. [24] Mozambique 194 BD ND 2.1
Cunha et al. [25] Mozambique 1231 BD M 1.4
346 BD F 1.8
Stokx et al. [26] Mozambique 609 BD M 0.0
70 BD F 0.0
Miller et al. [27] Tanzania 212 HV M 0.0
Menendez et al. [11] Tanzania 980 PW F 2.4
Tess et al. [28] Tanzania 221 HV M 1.8
295 HV F 0.7
Stark et al. [15] Tanzania 208 HV F 7.2
Msuya et al. [29] Tanzania 382 HV F 1.1
Puato et al. [30] Tanzania 750 HV ND 2.0
Oshitani et al. [31] Zambia 240 BD ND 0.0
343 IP ND 0.3
F, female; M, male; ND, not defined; PW, pregnant women; IP, inpatient; BD, blood donors; HV, healthy volunteer; HIV+, HIV positive.
Table 2 Estimated prevalence of HCV in Malawi and its neighbouring countries
Country Number of studies Cohort (n) HCV prevalence (%) SE 95% CI
Malawi (all) 5 3123 1.0 0.17 0.7–1.4
Malawi (healthy) 2 582 0.3 0.24 0.1–1.2
Mozambique (healthy) 3 2450 1.1 0.21 0.8–1.6
Tanzania (healthy) 5 3048 2.1 0.26 1.6–2.6
SE, standard error; CI, confidence interval. ‘Healthy’ is defined as male/female, non-inpatient and not declared HIV positive.
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in this region. Both factors may directly or indirectly play
a role in HCV transmission to women. A study by
Chimphambano et al. [20] examined HCV prevalence in
male and female Malawian prison inmates. While 86%
of the inmates reported being aware of intercourse
between male prisoners and 2.1% identified themselves
as being homosexual, HCV prevalence was reported to
be 0%. Injectable drug use was not reported in this
study. Only one study in Tanzania [21] has compared
HCV prevalence in this high-risk group, examining HCV
prevalence in 267 injecting drug users (IDU) and 163
drug users that had never injected (NIDU). The IDUs had
a HCV prevalence of 27.7% whereas that of NIDUs was
1.8%, although no confirmatory test was performed. A
further study [22] did not meet our inclusion criteria but
conducted research in 509 Tanzanian MSM and found
HCV prevalence to be 14%. IVDU is rare in women
compared to men, but data in our cohort for IVDU or
having contact/living with someone who was an active
intravenous drug user were not available to us and nei-
ther was the transfusion history and possibility of iatro-
genic spread for the mothers. The HCV-positive child
had no recorded blood transfusions, but information on
the child being breastfed by a wet nurse instead of its
mother or any other medical intervention was similarly
not available.
Malawi is known to have a high HIV prevalence [23],
and HIV infection is a known risk factor for HCV infec-
tion. However, neither of the HCV-infected women in
our study were HIV co-infected. HIV prevalence in paedi-
atric inpatients in Malawi has been reported to be 8.8%
[23], but the HCV-positive child in our cohort was also
HIV negative.
Therefore, we can only hypothesise that the mothers
may have acquired their HCV from having been either
breastfed as a child by somebody infected or from con-
tact with an infected partner or contaminated needles/
instruments or transfusions before transfusion screening
for bloodborne viruses was in place. The HCV-positive
child may have been infected through contact with con-
taminated needles/instruments or by being breastfed by a
HCV-positive wet nurse.
Our study has several strengths: the sample size studied
was large, children’s sera were matched, and both ELISA
screening and a more sensitive confirmatory test were
employed. We compared our data with HCV prevalence
of neighbouring countries by conducting a literature
review. The study’s limitation was the relative age of
sera, the fact that not all children were tested for HCV
irrespective of their mother’s results and that fresh whole
blood samples were not available to test for HCV RNA
and liver function.
In summary, we report that HCV is prevalent at low
levels in mothers living in Malawi. It is unclear how
these women acquired their infection. HCV high-risk
groups have not been studied in this region. Research
on these groups and their partners and children may
inform transmission prevention and eradication pro-
grammes.
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